Two PAREXEL Executives Named to 2017 PharmaVOICE 100
Chief Scientific Officer of PAREXEL and Worldwide Head of The Medical Affairs Company recognized for contributions to life sciences industry
BOSTON, August 1, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide Head of The Medical Affairs Company (TMAC), have been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2017 issue of PharmaVOICE, recognizes both leaders for their valuable contributions to the industry and dedication to improving patients’ lives, while also mentoring the next generation of industry leaders.
Dr. Pretorius has been with PAREXEL for more than 20 years in various international leadership roles. As Chief Scientific Officer, he collaborates closely with biopharmaceutical and medical device clients in designing and optimizing innovative drug / device development strategies and plans. He also leads several PAREXEL business units across three continents – including the Company’s global Early Phase business, Global Medical Services, Quantitative Clinical Development, as well as its Genomic Medicine unit.
Dr. Demestihas joined PAREXEL in February 2017, when the Company acquired TMAC, a leading full-service Contract Medical Organization (CMO). TMAC offers outsourced Medical Science Liaisons (MSLs), Clinical Nurse Educators (CNEs) and other field medical teams in addition to medical affairs consulting, medical information, and direct placement services. A 30-year veteran of the pharmaceutical industry, Dr. Demestihas has led TMAC from its founding in 2007. In 1997, Dr. Demestihas established the pharmaceutical industry’s first CMO, Science Oriented Solutions (SOS), and led the company for 10 years.
“We are proud that PharmaVOICE has recognized Dr. Sy Pretorius and Dr. Evan Demestihas among this year’s 100 most inspiring people in the life sciences industry. Their passion and dedication to drug development is felt throughout PAREXEL and beyond,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “Sy’s leadership in clinical trial innovation has helped PAREXEL expand our capabilities and service offerings to help our clients bring treatments to market faster and more efficiently. Evan is a pioneer in the medical affairs sector, who recognized a demand for medical affairs solutions across the industry and created a successful breakthrough business model. The leadership, innovation, and dedication that both Sy and Evan bring to PAREXEL inspire our global workforce each day.”
The annual PharmaVOICE 100 list honors a select group of leaders in the life sciences who positively impact their colleagues, peers, organizations, and the industry at large. These individuals are passionate, forward-thinkers who actively work to address industry challenges and trends. To read the 2017 PharmaVOICE profiles, visit www.pharmavoice.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #
Tel.: +1 781-434-4772
Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Tel.: +1 781-434-4753